tbuckley/cabot-search huggingface dataset:
The NEXT-2 (Next Generation Personalized Tx with Plasma DNA Genomics Trial-2 in Refractory Solid Tumors: cfDNA-Based Umbrella Trial, an interim analysis).
Authors: Seung Tae Kim, AmirAli Talasaz, Se Hoon Park, Won Ki Kang, Helmy Eltoukhy, Richard Burnham Lanman, Jeeyun Lee, Keunchil Park
Journal: Journal of Clinical Oncology (2015)

e12540 Background: The NEXT-2 trial is cfDNA genomics master protocol to enroll refractory cancer patients and to guide matched trial according to cfDNA genomics of 56 genes. Methods: Using Digital Sequencing technology (DST), the Guardant360 panel enables single-molecule sensitivity using current next-generation sequencers with nearly-perfect specificity despite a long target region of ~80,000 bases. The primary objective of this trial is to show that the matched therapy group has longer PFS than the non-matched group. Eligible criteria: patients with histologically confirmed metastatic gastric/lung cancer/rare cancer, who do not have sufficient biopsy material to undergo genomic profiling of their tumor, or do not have feasible biopsy sites. For the all three disease types, the expected median PFS is 4 months for the matched group and 2 months for the unmatched group. Assuming (i) exponential distributions for PFS, (ii) 3 months of additional FU and (iii) 25% of patients with matched mutations, N = 180 95% power by the 2-sample log-rank test with 2-sided alpha = 5%. Results: From August 2014 to December 2014, we accrued 51 patients (gastric, N = 30, lung cancer N = 5, rare cancer N = 13). At this time, we analyzed cfDNA of 47 patients. We identified at least one major alteration in 43 patients (91.5%). Of the 43 patients, eight patients are being treated with matched therapy or waiting for the matched clinical trial based on cfDNA results. One GC patients with both ERBB2 and EGFR amplification is responding to lapatinib after failing four prior cytotoxic regimens. The trial is currently ongoing. Patients with PIK3CA E542K, PIK3CAH1047R are waiting for AKT/mTOR inhibitor trial upon progression.Conclusions: This trial is the first basket trial based on cfDNA genomics. Based on the 4 arms in this trial where we looked for ERBB2 amplification or mutations in EGFR, KIT and BRAF, we provide evidence that cfDNA can guide to matched therapy or trials in 17% of the enrolled patients in whom insufficient or unobtainable tissue was available for genomic analysis. Our interim results suggest that digital sequencing of cfDNA may be an effective biopsy-free alternative in advanced cancer. Clinical trial information: NCT02140463.
Afatinib efficacy and cerebrospinal fluid concentration in NSCLC patients with EGFR mutation developing leptomeningeal carcinomatosis
Authors: A. Tamiya, M. Tamiya, T. Nishihara, T. Shiroyama, K. Nakao, T. Tsuji, N. Takeuchi, S.-I. Isa, N. Omachi, N. Okamoto, H. Suzuki, K. Okishio, A. Iwazaki, K. Imai, T. Hirashima, S. Atagi
Journal: Annals of Oncology (2016)
Analysis of Prognosis in Follicular Lymphoma According to the FLIPI.
Authors: Chizuko Hashimoto, Heiwa Kanamori, Naoto Tomita, Maki Takabayashi, Etsuko Yamazaki, Koji Ogawa, Michiko Hattori, Hiroyuki Fujita, Shin Fujisawa, Shigeki Motomura, Fumio Kodama, Yoshiaki Ishigatsubo
Journal: Blood (2005)
EBV Can Induce Somatic Hypermutation in Naïve B Cells In Vitro but Ig Class Switching Requires T Cell Help.
Authors: Sridhar Chaganti, Noelia Begue Pastor, Gouri Baldwin, Claire Shannon-Lowe, Regina Feederle, Debbie Croom-Carter, Juliana Stylianou, Andrew I. Bell, Alan B. Rickinson, Henri-Jacques Delecluse
Journal: Blood (2006)
Muscular dystrophy meets protein biochemistry, the mother of invention
Authors: Steven D. Funk, Jeffrey H. Miner
Journal: Journal of Clinical Investigation (2017)

Muscular dystrophies result from a defect in the linkage between the muscle fiber cytoskeleton and the basement membrane (BM). Congenital muscular dystrophy type MDC1A is caused by mutations in laminin α2 that either reduce its expression or impair its ability to polymerize within the muscle fiber BM. Defects in this BM lead to muscle fiber damage from the force of contraction. In this issue of the JCI, McKee and colleagues use a laminin polymerization-competent, designer chimeric BM protein in vivo to restore function of a polymerization-defective laminin, leading to normalized muscle structure and strength in a mouse model of MDC1A. Delivery of such a protein to patients could ameliorate many aspects of their disease.
Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial
Authors: Eileen Mary Boyle, Marie-Odile Petillon, Charles Herbaux, Johanna Mimouni, Xavier Leleu, Lionel Karlin, Chantal Doyen, Marc Wetterwald, Muriel Roussel, Cyrille Hulin, Bruno Royer, Margaret Macro, Philippe Moreau, Karel Fostier, Mamoun Dib, Sabine Brechignac, Caroline Bureau, Gerald Marit, Adrian Tempescul, Marie Lorraine Chretien, Charles Zarnitsky, Cecile Fohrer, Aurore Perrot, Lotfi Benboubker, Laurent Voillat, Jean Valere Malfuson, Clara Mariette, Mourad Tiab, Sophie Rigaudeau, Arnaud Jaccard, Anne-Marie Stoppa, Laure Vincent, Jean Claude Eisenmann, Laurent Frenzel, Bertrand Arnulf, Mohamad Mohty, Philippe Rodon, Brigitte Kolb, Olivier Decaux, Pascal Godmer, David Beauvais, Benjamin Carpentier, Sarah Bonnet, Thomas Longval, Mathieu Dewevre, Herve Avet-Loiseau, Michel Attal, Susanna Schraen, Thierry Facon
Journal: Blood (2016)
PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma
Authors: Guru Sonpavde
Journal: New England Journal of Medicine (2017)

For more than two decades, the only therapy that was proven to extend overall survival among patients with advanced urothelial carcinoma was cisplatin-based combination chemotherapy.1 First-line cisplatin-based chemotherapy yields a median overall survival of 14 to 15 months, coupled with 5-year survival among 5 to 15% of patients. Historically, salvage chemotherapy with vinflunine or a taxane after the receipt of platinum-based chemotherapy has resulted in a response in only approximately 10% of patients, with a dismal median overall survival of 6 to 8 months.2,3 Vinflunine was approved in multiple countries on the basis of a phase 3 trial that . . .
Overall survival benefit with masitinib mesylate in imatinib-naive, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-years follow-up of the French Sarcoma Group phase II trial.
Authors: J. Blay, A. Le Cesne, N. Bin Bui, O. Bouche, A. Adenis, D. Julien, A. Cioffi, A. Moussy, O. Hermine
Journal: Journal of Clinical Oncology (2011)

85 Background: Masitinib is a novel tyrosine kinase inhibitor which, in vitro, has greater activity and selectivity than imatinib (IM) against both wild-type KIT receptor and its mutated form in the juxtamembrane region (IC 50=100 nM versus 200 nM for IM, 3 nM versus 27nM and 40 nM versus 120nM, respectively, for exons 9,11, and 13). This multicenter phase II study evaluated efficacy and safety of masitinib as a first-line treatment of advanced GIST. Methods: IM-naïve patients with inoperable, locally advanced or metastatic GIST received oral masitinib (7.5 mg/kg/day) until progression, refusal or toxicity. Efficacy variables included response rate, best response (RECIST), progression-free survival (PFS) and overall survival (OS). Initial results were previously reported in EJC 2010. We present here the same series with updated PFS and OS (median follow up of 48 months). Results: 30 patients with a median age of 58 years (60% of males) were included from June 2005 to April 2007 in five French institutions. At the cut-off date (31 august 2010), 9 patients are still under treatment with a median treatment duration of 41 months (min=33, max=52). Two additional progressions have been reported for a total of 14 events (13 progressions and 1 death). Updated median PFS is 41 months (95% CI: [17.5; NR]) with PFS rates of 60% [39; 77], 56% [35; 73] and 45% [24; 64] respectively at 2, 3 and 4 years. With 8 patients dead, median OS is not yet reached with OS rates of 90% [72; 97], 87% [68; 95] and 74% [52; 87], respectively, at 2, 3, and 4 years. The main frequent relevant grade 3 toxicities were: rash (10%), neutropenia (7%) and abdominal pain (7%) with one patient presented a grade 4 skin exfoliation. No other relevant long-term toxicities were reported and no more patients discontinued treatment due to suspected toxicity. Conclusions: The long term results observed with masitinib confirm a very interesting activity with prolonged PFS and OS. These results support the head to head comparison with imatinib in the currently ongoing phase III randomized clinical trial in first line locally advanced or metastatic GIST patients. [Table: see text]
Detection and Treatment of Molecular Relapse in Acute Myeloid Leukemia with RUNX1, CBFB or MLL Gene Translocations. Frequent Quantitative Monitoring of Molecular Markers in Different Compartments and Correlation with WT1 Gene Expression.
Authors: Michael Doubek, Ivo Palasek, Zdenek Pospisil, Sona Struncova, Dana Dvorakova, Marek Borsky, Martin Klabusay, Yvona Brychtova, Marta Krejci, Jiri Mayer
Journal: Blood (2007)
Inhibition of Both Activated p38 Mapkα and mTORC1 Potentiates the Effect of SR1 on Promoting Hematopoietic Reconstitution of Ex Vivo Expanded Human Umbilical Cord Blood Hematopoietic Stem Cells
Authors: Xiao Ma, Xiaoyi Li, Danyue Peng, Huifang Wang, Lei Li, Hao Zhou, Daohong Zhou, Yi Luo, Lingbo Liu
Journal: Blood (2016)
Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,
Authors: Luis F. Porrata, Kay M. Ristow, Joseph P. Colgan, Thomas M. Habermann, Thomas E. Witzig, David James Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Grzegorz S. Nowakowski, Carrie A. Thompson, Svetomir N. Markovic
Journal: Blood (2011)
STMC-25. GPR133 PROMOTES HYPOXIA-DRIVEN TUMOR PROGRESSION IN GLIOBLASTOMA
Authors: Joshua Frenster, N. Sumru Bayin, Josh Robert Kane, Jordan Rubenstein, Aram Modrek, Rabaa Baitamal, Igor Dolgalev, Katie Rudzenski, Matija Snuderl, John Golfinos, Werner Doyle, Donato Pacione, Andrew Chi, Adriana Heguy, Nadim Shohdy, Douglas MacNeil, Xinyan Huang, Erik Parker, David Zagzag, Dimitris Placantonakis
Journal: Neuro-Oncology (2016)

A hallmark of Glioblastoma (GBM) is an intratumoral gradient of oxygen tension, which includes both vascular areas and poorly vascularized regions of hypoxia. Hypoxia has been reported to promote the GBM stem cell (GSC) phenotype and lead to tumor progression. The majority of the hypoxic response is regulated through the Hypoxia Inducible Factors (Hifs). However, attempts to therapeutically target Hifs have been unsuccessful. Finding other means of targeting hypoxia-driven GBM progression remains an important quest. We recently found that GPR133 (ADGRD1), an orphan adhesion G-protein coupled receptor (GPCR), is enriched in CD133-expressing GSCs (n=3 biospecimens; P<0.04), at the mRNA and protein level. Immunohistochemical staining of 9 GBM biospecimens revealed that GPR133 is restricted to hypoxic areas of pseudopalisading necrosis, which also express hypoxic markers Hif1a and CA9. No GPR133 staining was observed in normal brain. Induction of hypoxia in patient-derived GBM cultures led to upregulation of GPR133 transcript (n=5 cultures; P<0.008). Consistent with the hypothesis that GPR133 expression is regulated by oxygen tension, we found multiple hypoxia response elements (HRE) in the genomic locus of GPR133 and Hif1a knockdown decreased the level of GPR133 transcript (P<0.05). GPR133 knockdown decreased the CD133+ cell population, tumor cell proliferation and tumorsphere formation in vitro under both normoxic and hypoxic conditions (P<0.05). GPR133 knockdown essentially abolished in vivo tumor xenograft initiation (P<0.002) and prevented the death of mouse hosts (n=4 mice/group; P<0.01). GPR133 knockdown decreased intracellular cAMP levels (P<0.05), and forskolin rescued the in vitro knockdown phenotype (P<0.03), suggesting that GPR133 signals through intracellular cAMP. Finally, analysis of TCGA data from 160 GBM patients reveals that higher GPR133 mRNA levels correlate with worse survival (P=0.0062). In summary, our findings offer compelling evidence that GPR133 plays an important pro-tumorigenic role in GBM, especially in the context of hypoxia, and represents a novel therapeutic target.
GENT-13. IMMUNOMETHYLOMIC ASSAY OF BLOOD NEUTROPHIL LYMPHOCYTE RATIO (NLR) IN GLIOMA SURVIVAL
Authors: John Wiencke, Devin Koestler, Annette Molinaro, Joseph Wiemels, Ritu Roy, Helen Hansen, Terri Rice, Paige Bracci, Lucie McCoy, Karl Kelsey, Margaret Wrensch, Brock Christensen
Journal: Neuro-Oncology (2016)

Differentially methylated regions (DMRs) within DNA isolated from whole blood can be used to estimate the proportions of circulating leukocyte subtypes. This immunomethylomic approach was applied to peripheral blood DNA from 72 glioma patients with molecularly defined tumors, representing common patient groups with characteristic survival times and risk factors. We estimated the neutrophil to lymphocyte ratio (NLR) using deconvolution algorithms with reference DMR libraries from isolated leukocyte populations and Illumina 450K DNA methylation data. The methylation-derived NLR (mdNLR) may be a surrogate indicator of immunosuppressive myeloid cells in cancer patients. A distribution of mdNLR scores was observed in glioma patients; decreased survival times were associated with ratios >4.0. In Cox proportional hazard models the mdNLR was found to be associated with survival independent of known risk factors including, age, gender, grade, and molecular subtype. Hazard ratios for mdNLR were little affected in models including prior chemotherapy or dexamethasone. We used the mdNLR to further explore potentially novel methylation biomarkers by identifying mdNLR associated DMRs that were not contained within known DMR libraries of isolated leukocytes. Gene ontology analysis showed that these novel mdNLR associated loci were enriched for myeloid and immune pathways. The NLR based on DNA methylation can be applied to archival blood samples and is associated with glioma survival independent of known risk factors. Finally, the mdNLR provides a novel discovery method to uncover methylation biomarkers that may represent potential immunosuppressive myeloid cells within the blood of glioma patients.
Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT study
Authors: E.M. Wolin, G.A. Fisher,, P.L. Kunz, N. Liyanage, S.P. Lowenthal, B. Mirakhur, R.F. Pommier, M. Shaheen, A. Vinik
Journal: Annals of Oncology (2016)
Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): Analysis of disparities in care.
Authors: B. A. Murphy, A. Y. Chen, W. J. Curran, A. S. Garden, P. M. Harari, S. J. Wong, L. A. Bellm, M. Schwartz, J. Newman, D. Adkins, D. N. Hayes, U. Parvathaneni, D. Brachman, B. Ghabach, C. Schneider, M. Greenberg, A. Abitbol, P. R. Anne, K. K. Ang
Journal: Journal of Clinical Oncology (2011)

5533 Background: We sought to examine differences in treatment by various populations in LORHAN, a national registry of head and neck carcinoma (HNC) patients (pts). Methods: Pts included in the analysis had de novo, stage III/IV, non-metastatic HNC, received radiotherapy (RT) and/or drug therapy, were ≥18 years of age and had provided written informed consent. Univariate analyses (UA) and multivariable logistic regression (LR) were used to assess relationship of pre-specified independent variables to selected treatment related dichotomous measures. Results: UA results are in table below. LR showed the following factors were significantly associated with use of RT alone: community setting (odds ratio [OR] 0.45; 95% CI, 0.30-0.67); age (OR 1.03; 95% CI, 1.01 - 1.05); black race (OR 1.9; 95% CI 1.1-3.0); Hispanic ethnicity (OR 3.5; 95% CI, 1.5-7.6). Factors significantly associated with use of surgery were: community setting (OR 0.54; 95% CI, 0.42-0.69) and age (OR 0.9877; 95% CI, 0.9766 - 0.9989). Conclusions: This analysis suggests setting, age and race may influence treatment received for HNC. Further investigation required to confirm findings here. Treatment comparison: Primary RT versus concurrent chemoradiation (CRT). Variable Intergroup comparisons All N=1,359 Primary CRT n=1,194 Primary RT n=165 P value No. % No. % No. % Setting Academic 864 64 738 62 126 76 0.0003 Community 495 36 456 38 39 24 Age (years) Mean 58 58 61 0.007 Ethnicity White (non-Hispanic origin) 1,108 82 986 83 122 74 0.009 Black (non-Hispanic origin) 163 12 133 11 30 18 Hispanic 39 3 30 3 9 6 Asian 22 2 19 2 3 2 Other 27 2 26 2 1 <1 Insurance status Does not have insurance 72 5 70 6 2 1 0.003 Has insurance 648 48 580 49 68 41 Unknown 639 47 544 46 95 58 Type of insurance Private 401 30 361 30 40 24 0.02 Medicaid 75 6 68 6 7 4 Medicare 141 10 125 11 16 10 Military/VA 29 2 24 2 5 3 No insurance 72 5 70 6 2 1 Unknown 641 47 546 46 95 58 Household income NS Highest education level NS Treatment comparison: Surgery vs. no surgery before RT or CRT. Variable Intergroup comparisons All N=1,826 No surgery n=1,359 surgery n=467 P value No. % No. % No. % Setting Academic 1,220 67 864 64 356 76 <0.0001 Community 606 33 495 36 111 24 Age (years) Mean 58 58 57 0.006 Other variables (as noted above) NS Abbreviation: NS, not significant.
OS6.7 Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies: results from the IasON trial
Authors: G. Berzero, E. Karantoni, C. Dehais, F. Ducray, J. De Seze, G. Picard, V. Rogemond, J. Honnorat, J. Delattre, D. Psimaras
Journal: Neuro-Oncology (2016)
A phase I study of sonidegib (S) in combination with docetaxel (D) in patients (pts) with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study)
Authors: M. Martín, M. Ruiz-Borrego, J.M. Trigo Perez, S. Antolín, J.A. García-Sáenz, J. Corral, Y. Jerez, A. Urruticoechea, H. Colom, N. Gonzalo, C. Muñoz, J. Cuevas, C. del Monte, L. Pérez-Ramos, R. Caro, A. Blach, S. Benito, S. Bezares Montes, E. Carrasco, F. Rojo
Journal: Annals of Oncology (2016)
RARE-06. SINONASAL UNDIFFERENTIATED CARCINOMA (SNUC): INCIDENCE OF CNS INVOLVEMENT
Authors: Marc Chamberlain, Cristina Rodriquez, Jay Liao
Journal: Neuro-Oncology (2016)

Sinonasal undifferentiated carcinomas (SNUC) are rare sinonasal tumors associated with an aggressive clinical course that frequently invades the central nervous system (CNS). A retrospective review of outcomes of all patients with SNUC evaluated at the University of Washington from 1992 to 2016. 31 patients with pathologically confirmed SNUC were identified. One was lost to follow up before treatment initiation. Median age at diagnosis was 50 years (range 22-82), 18(60%) were male, 16(53%) were past or recent smokers and 25 (83%) were non-Hispanic Caucasian. TNM distribution was as follows: 2 - T2, 4 - T3 and 24 - T4 tumors; 23 - N0, 7 - N2; and 1 - M1.CNS involvement at diagnosis was present in 19 (63%), with disease invading the cribriform plate in 5(17%), anterior cranial fossa in 11(37%), and skull base in 5(16%). Primary therapy included surgical resection in 15(50%). 28(93%: median dose 70 Gy, range 54-72) received radiotherapy, primarily with photon- based treatment, 2 with protons and 2 received additional Gamma Knife radiosurgery boost. Chemotherapy was administered to 28(93%: platinum-based in 26); in 5 neoadjuvant, 25 concurrent with radiation and 5 post-radiation. 6(23%) patients had refractory disease, half involving the CNS. 12 (40%) patients had recurrence; 5 involved the CNS directly (3 frontal brain metastases; 3 leptomeningeal metastases) and 1 indirectly (epidural spinal cord compression). At last follow up, 13(43%) patients are alive including 1 with progressive CNS disease and 1 with CNS treatment-related complications. 17(57%) patients have died, including 6 as a result of CNS disease progression and 1 CNS treatment-related complication (CSF leak with meningitis). SNUC have a high rate of CNS invasion at presentation as well as at recurrence. Involvement of the CNS is associated with poor outcomes and represents a cohort in need of improved therapy.
Tubular Damage Is Ubiquitous in Newly-Diagnosed Patients with Multiple Myeloma: Comparison of Three Urinary and Two Serum Markers of Kidney Injury.
Authors: Meletios A Dimopoulos, Dimitrios Christoulas, Efstathios Kastritis, Maria Gkotzamanidou, Alexandra Margeli, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Ioannis Papassotiriou, Evangelos Terpos
Journal: Blood (2012)
A multi-centre study to investigate the natural history of taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast or prostate cancer
Authors: R. Fernandes, S. Mazzarello, M.F. Ibrahim, J. Hilton, A. Joy, M. Ong, B. Hutton, L. Vandermeer, M. Clemons
Journal: Annals of Oncology (2016)
ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)–naive, advanced anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC)
Authors: S. Popat, M. Tiseo, S. Gettinger, S. Peters, J. Haney, D. Kerstein, D.R. Camidge
Journal: Annals of Oncology (2016)
Identification of a Novel T-ALL Entity with NKX2-1/NKX2-2 Rearrangements
Authors: Irene Homminga, Rob Pieters, Anton Langerak, Johan de Rooi, Andrew Stubbs, Monique Verstegen, Maartje Vuerhard, Jessica Buijs-Gladdines, Clarissa Kooi, Petra Klous, Pieter Van lierberghe, Adolfo Ferrando, Jean-Michel Cayuela, Brenda Verhaaf, Berna Beverloo, Martin A. Horstmann, Valerie de Haas, Anna-Sophia Wiekmeijer, Karin Pike-Overzet, Frank Staal, Wouter de Laat, Jean Soulier, Francois Sigaux, Jules P.P. Meijerink
Journal: Blood (2010)
MPTH-60. A RARE CASE OF CRYSTAL-STORING HISTIOCYTOSIS IN THE BRAINSTEM AND CEREBELLUM
Authors: Justin Low, James Wang, Margaret Flanagan, C. Dirk Keene, David Louis, Gordana Juric-Sekhar, Maciej Mrugala, Gwen Garden
Journal: Neuro-Oncology (2016)

We present an unusual case of a 37-year old male who presented with a three-week history of diplopia, vertigo, left facial numbness, and left facial droop. MRI demonstrated a contrast enhancing mass at the left pontomedullary junction and extending into the cerebellum. Biopsy was consistent with crystal-storing histiocytosis, which is characterized by abnormal cytoplasmic aggregation of immunoglobulin crystals in histiocytes. To our knowledge, this is the first case of crystal-storing histiocytosis described in the brainstem and cerebellum and one of only a handful described in the central nervous system. This rare disorder is usually associated with underlying lymphoplasmacytic disorders or less commonly inflammatory or infectious disease. However, none of these have been identified thus far in this case. The patient received a short oral steroid course with resultant radiologic normalization. We review the crystal-storing histiocytosis literature and propose continued regular surveillance for the development of lymphoplasmacytic disease.
Superior Therapeutic Efficacy of Chimeric Antigen Receptor Modified T Cells Against CD19 over Chemotherapy in Relapsed/Refractory Acute Lymphocytic Leukemia
Authors: Yongxian Hu, Jian Yu, Yi Luo, Jimin Shi, Zhao Wu, Guoqing Wei, Jie Sun, Zhen Cai, Lei Xiao, He Huang
Journal: Blood (2016)